Published in Lancet on April 04, 1987
Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. Br J Clin Pharmacol (2001) 0.86
The measurement of haloperidol and reduced haloperidol in hair as an index of dosage history. Br J Clin Pharmacol (1990) 0.83
Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia. J Psychiatry Neurosci (1994) 0.77
Standardized remission criteria in schizophrenia. Acta Psychiatr Scand (2006) 3.29
Tolerance and withdrawal with zolpidem. Lancet (1993) 1.97
Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol (1998) 1.51
Psychopathological and cognitive features in subclinical hypothyroidism. Prog Neuropsychopharmacol Biol Psychiatry (1997) 1.22
Influence of age on mianserin pharmacokinetics. Psychopharmacology (Berl) (1982) 1.13
Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry (1993) 1.08
[Multinational validation of the Composite International Diagnostic Interview (CIDI)]. Minerva Psichiatr (1994) 1.03
Interactions between transcranial direct current stimulation (tDCS) and pharmacological interventions in the Major Depressive Episode: findings from a naturalistic study. Eur Psychiatry (2012) 1.02
Medically unexplained somatic symptoms in different cultures. A preliminary report from phase I of the World Health Organization International Study of Somatoform Disorders. Psychother Psychosom (1995) 0.99
Helicobacter pylori impairs iron absorption in infected individuals. Dig Liver Dis (2004) 0.99
Long-term treatment with mianserin: a clinical study with plasma levels. Adv Biochem Psychopharmacol (1982) 0.95
Transcranial direct current stimulation for the outpatient treatment of poor-responder depressed patients. Eur Psychiatry (2011) 0.93
Olanzapine-induced neutropenia after clozapine-induced neutropenia. Lancet (1999) 0.93
Plasma concentrations, information and therapy adherence during long-term treatment with antidepressants. Br J Clin Pharmacol (1985) 0.92
'Theory' of mind impairment in patients affected by schizophrenia and in their parents. Schizophr Res (2009) 0.91
Conventional vs controlled-release carbamazepine: a multicentre, double-blind, cross-over study. Acta Neurol Scand (1990) 0.89
Psychiatric diagnosis and aggression before acute hospitalisation. Eur Psychiatry (2007) 0.88
Temporal lobe grey matter volume in schizophrenia is associated with a genetic polymorphism influencing glycogen synthase kinase 3-β activity. Genes Brain Behav (2010) 0.84
Dermatitis herpetiformis and gluten-sensitive enteropathy in a patient with nodular prurigo. J Eur Acad Dermatol Venereol (2002) 0.84
[2-COM: presentation of an instrument facilitating communication between physicians and carers in daily practice]. Encephale (2007) 0.83
Plasma renin activity in depressed patients treated with increasing doses of lithium carbonate. Psychopharmacologia (1975) 0.83
A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics. Prog Neuropsychopharmacol Biol Psychiatry (2001) 0.83
Increased risk of surgery in undiagnosed celiac disease. Dig Dis Sci (2001) 0.82
Emotional reactivity in chronic schizophrenia: structural and functional brain correlates and the influence of adverse childhood experiences. Psychol Med (2010) 0.82
Factors involved in the level of functioning of patients with schizophrenia according to latent variable modeling. Eur Psychiatry (2011) 0.82
Computer-aided neurocognitive remediation in schizophrenia: durability of rehabilitation outcomes in a follow-up study. Neuropsychol Rehabil (2010) 0.82
Management of physical health in patients with schizophrenia: international insights. Eur Psychiatry (2010) 0.81
Adenylate cyclase from Hirudo medicinalis segmental ganglia: modulation by physiological and non-physiological agents. Comp Biochem Physiol C (1992) 0.80
Progranulin gene variability and plasma levels in bipolar disorder and schizophrenia. PLoS One (2012) 0.80
Suicide attempts in schizophrenic patients: clinical variables. Asian J Psychiatr (2013) 0.80
Plasma and brain pharmacokinetics of mianserin after single and multiple dosing in mice. Prog Neuropsychopharmacol Biol Psychiatry (1987) 0.79
Alcoholism and depression: a placebo controlled study with viloxazine. Int J Clin Pharmacol Res (1990) 0.79
Alternative prophylactic treatments to lithium in bipolar disorders. Clin Neuropharmacol (1990) 0.79
Quazepam versus triazolam in patients with sleep disorders: a double-blind study. Int J Clin Pharmacol Res (1993) 0.79
Duration of untreated illness as a predictor of treatment response and remission in obsessive-compulsive disorder. World J Biol Psychiatry (2010) 0.78
Diagnosis and treatment of obsessive-compulsive disorder and related disorders. Int J Clin Pract (2007) 0.78
Clinical activity and tolerability of trazodone, mianserin, and amitriptyline in elderly subjects with major depression: a controlled multicenter trial. Clin Neuropharmacol (1989) 0.78
Citalopram concentrations and response in obsessive-compulsive disorder. Preliminary results. CNS Drugs (2004) 0.77
Combination therapy with haloperidol and orphenadrine in schizophrenia. A clinical and pharmacokinetic study. Encephale (1986) 0.77
Safety of SSRIs during pregnancy: a controlled study. Hum Psychopharmacol (2012) 0.77
Depression in schizophrenia: clinical and pharmacological variables. Schizophr Res (1995) 0.77
Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients. Psychopharmacology (Berl) (1985) 0.77
Therapeutic plasma levels of some anticonvulsants in focal epilepsy in relation to computerized axial tomography. Encephale (1981) 0.77
Aggression and psychopharmacological treatments in major psychosis and personality disorders during hospitalisation. Prog Neuropsychopharmacol Biol Psychiatry (2011) 0.77
Factors affecting the clinical response to haloperidol therapy in schizophrenia. Clin Neuropharmacol (1990) 0.77
Plasma and intracellular kinetics of lithium after oral administration of various lithium salts. Eur J Clin Pharmacol (1977) 0.76
A functional comparison of patients with schizophrenia between the North and South of Europe. Eur Psychiatry (2011) 0.76
Clinical outcome and tolerability of duloxetine in the treatment of major depressive disorder: a 12-week study with plasma levels. J Psychopharmacol (2009) 0.76
Animal model for investigation of fluphenazine kinetics after administration of long-acting esters. Biopharm Drug Dispos (1981) 0.76
Residual neuroleptic-induced parkinsonian symptoms in schizophrenia. A naturalistic study with orphenadrine. Pharmacopsychiatry (1989) 0.76
Unwanted effects of fluphenazine enanthate and decanoate. Lancet (1979) 0.76
Orphenadrine plasma levels and amelioration of extrapyramidal side effects in schizophrenic patients treated with haloperidol. Acta Neurol (Napoli) (1986) 0.76
Clonazepam/haloperidol combination therapy in schizophrenia: a double blind study. Acta Psychiatr Scand (1987) 0.75
Prediction of response to haloperidol in schizophrenia: neuroendocrine, neuromorphological and clinical variables. Int Clin Psychopharmacol (1994) 0.75
Comment on 'reduced haloperidol does not interfere with antipsychotic activity of halperidol in the treatment of acute schizophrenia'. Int Clin Psychopharmacol (2000) 0.75
Hypothalamic-pituitary-adrenal axis in schizophrenia. Biol Psychiatry (1996) 0.75
Prevalence and risk factors for tardive dyskinesia: a study in an Italian population of chronic schizophrenics. Eur Arch Psychiatry Clin Neurosci (1990) 0.75
Age, therapeutic "milieu" and clinical outcome in depressive patients treated with viloxazine: a study with plasma levels. Prog Neuropsychopharmacol Biol Psychiatry (1986) 0.75
Mianserin metabolites. Br J Clin Pharmacol (1983) 0.75
Smooth pursuit eye movements and saccadic eye movements in patients with delusional disorder. Am J Psychiatry (1993) 0.75
Antiprostatic effect of cimetidine in rats. Agents Actions (1987) 0.75
Health care costs of therapy-refractory schizophrenic patients treated with clozapine: a study in a community psychiatric service in Italy. Acta Psychiatr Scand (1999) 0.75
Epidermal growth factor stimulation of lecithin release by human amnion. Gynecol Obstet Invest (1994) 0.75
[Accident prevention. Planning and health education experience]. Minerva Pediatr (1985) 0.75
Plasma renin activity in primary and secondary depression. Arch Psychiatr Nervenkr (1970) (1977) 0.75
[Education, culture, and socialization of immigrants; activities and proposals of the Council of Europe]. Studi Emigr (1980) 0.75
Adenylate cyclase activity from Hirudo medicinalis segmental ganglia: modulation by temperature and Mg2+ ions. Comp Biochem Physiol Pharmacol Toxicol Endocrinol (1994) 0.75
Delusional AIDS and depression. Br J Psychiatry (1988) 0.75
Hydroxyhaloperidol and clinical outcome in schizophrenia. Psychopharmacol Ser (1989) 0.75
The effects of mianserin therapy on plasma renin activity in depressed patients. Biol Psychiatry (1986) 0.75
Olfactory transduction mechanisms in sheep. Neurochem Res (1995) 0.75
Renin and depression. Br J Psychiatry (1978) 0.75
Pharmacokinetics and adverse effects of single doses of dothiepin in young and elderly subjects. Prog Neuropsychopharmacol Biol Psychiatry (1990) 0.75
Cobalt-induced experimental epilepsy in cats pharmacologically immunodepressed. An EEG and histological study. Arzneimittelforschung (1976) 0.75
Age-related differences in kinetics and side-effects of viloxazine in man and their clinical implications. Psychopharmacology (Berl) (1983) 0.75
N1-Methylnicotinamide urinary output in multiple sclerosis affected patients. Acta Vitaminol Enzymol (1975) 0.75
[Controlled clinical study on the effect of quazepam versus triazolam in patients with sleep disorders]. Minerva Psichiatr (1990) 0.75
Reduced haloperidol/haloperidol ratio and clinical outcome in schizophrenia: preliminary evidences. Prog Neuropsychopharmacol Biol Psychiatry (1988) 0.75
Trazodone in late life depressive states: a double-blind multicenter study versus amitriptyline and mianserin. Psychopharmacology (Berl) (1988) 0.75
PB:PRM ratio in patients with epilepsy treated with primidone. Int J Clin Pharmacol Res (1983) 0.75
[Valpromide (Depamide) in the treatment of acute psychotic states. Open clinical study]. Acta Psychiatr Belg (1986) 0.75
Meeting report: The Emory University-San Raffaele cognition satellite meeting. Schizophr Res (2008) 0.75
Fluphenazine decanoate in acute and maintenance therapy of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (1987) 0.75
Prophylactic treatment with mianserin, therapy adherence and plasma monitoring. A case report. Acta Psychiatr Scand (1986) 0.75
An immunological approach to the treatment of epilepsy. Agressologie (1976) 0.75
[Neurotransmitters and experimental epilepsy. Study of the activity of various enzymes involved in their synthesis in rats with cobalt powder-induced epilepsy]. Acta Neurol (Napoli) (1978) 0.75
A new philosophy for schizophrenia care. Int J Psychiatry Clin Pract (2000) 0.75
Rare presentation of tardive dyskinesia. Am J Psychiatry (1992) 0.75
Therapeutic attempts with lithium in young drug addicts. Acta Psychiatr Scand (1975) 0.75
Two new formylated peptides able to activate chemotaxis and respiratory burst selectively as tools for studying human neutrophil responses. Cell Signal (1994) 0.75
[Pathogenetic considerations on the method of development of experimental co-induced epilepsy based on ultrastructural data]. Acta Neurol (Napoli) (1975) 0.75
[Neurochemical, immunological and ultrastructural aspects of experimental epilepsy. Critical review of current data]. Acta Neurol (Napoli) (1974) 0.75
Is olanzapine better than haloperidol in resistant schizophrenia? A double-blind study in partial responders. Int J Psychiatry Clin Pract (2002) 0.75
Hyperbaric oxygen induced experimental epilepsy: the age factor. Ital J Neurol Sci (1986) 0.75
2-COM: an instrument to facilitate patient-professional communication in routine clinical practice. Acta Psychiatr Scand (2002) 0.75
The association between insight and symptoms in bipolar inpatients: an Italian prospective study. Eur Psychiatry (2011) 0.75